Business Wire

NetApp Powers Porsche Motorsport to ABB FIA Formula E World Championship Wins with Data-driven Cloud Solutions

13.7.2022 15:00:00 EEST | Business Wire | Press release

Share

NetApp® (NASDAQ: NTAP), a global cloud-led, data-centric software company, and TAG Heuer Porsche Formula E Team, today announced a multi-year partnership. NetApp will provide the sportscar maker with innovative hybrid cloud solutions that will help them continue to write car racing history.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220713005218/en/

Porsche AG, a global automotive brand owned by Volkswagen Group, has begun shifting production towards electric or e-fuel powered vehicles in 2015. By the year 2030, Porsche AG aims for 80% of all vehicles sold to be electric. Tapping into NetApp’s real-time data services, TAG Heuer Porsche Formula E Team helps deliver on the vision of sustainable mobility while enabling the real-time adjustments that deliver superior race performance – and help drive the next generation of Porsche electric vehicles.

Real-time data collaboration service for the racetrack

NetApp's hybrid cloud solutions enable TAG Heuer Porsche Formula E Team to access their data trackside to support driver and team performance. This helps them make data-driven decisions in real-time, for example when to use the Formula E Attack Mode, which unlocks an additional 30 kilowatts of engine power. The rules about engaging Attack Mode are set by FIA shortly before every ePrix, hence it has a great impact on race strategy.

With data at the core of racing, business, and engineering decisions, the TAG Heuer Porsche Formula E Team requires cutting-edge data management technology:

  • Data and systems need to be available at the racetrack and fulfill demanding performance requirements.
  • Digital data collected during the ePrix must be uploaded to the cloud for analysis while the race is still running.
  • Cloud data needs to be processed by the team at Porsche Motorsport headquarters in Weissach, Germany for R&D.
  • After the race, data must be transferred to the cloud so it can be utilized in the future, and to support crucial data services such as backup and archiving.

The hybrid cloud data solution designed by NetApp and Porsche in response combines cloud network-attached (NAS) storage services with Global File Cache to ensure data can flow seamlessly and quickly between different widely dispersed locations. It also integrates powerful NetApp data services to ensure version consistency, manage and monitor cloud resources, and protect Porsche’s intellectual property:

  • Cloud Volumes ONTAP is the primary storage platform for TAG Heuer Porsche Formula E Team. The multicloud solution deployed on Azure acts as a hub that consolidates all the team’s data.
  • Global File Cache, the cloud volume edge capability provides local edge instances, enabling low-latency access to a common dataset, both at the on-premises development center in Weissach and the racetrack.
  • Cloud Manager delivers centralized orchestration across hybrid cloud storage infrastructure and all data management services, so that TAG Heuer Porsche Formula E Team can manage, monitor and automate all their data software and hardware consumption.
  • Cloud Backup integrates as backup and archive layer for the consolidated cloud data.

“Formula E is a technology showcase and R&D backbone for Porsche and preserves our strong motorsports heritage on the road and on the track,” said Friedemann Kurz, Head of Motorsport IT, Porsche. “Data is the defining element here, but it is not easy to harness when the racing team is always on the road. The solution created by NetApp is unique in the market in how it can move huge amounts of data at high speed while delivering an intuitive experience across edge, core and cloud so we can design better, faster cars for our racecar drivers and car enthusiasts everywhere.”

“This is a winning partnership in which two champions meet eye-to-eye. Porsche has secured over 30,000 wins in all major car racing series. NetApp has submitted more than 2,500 data innovation patents. Joining forces now, we are working to make our mark on the future of racing,” said James Whitemore, Executive Vice President and Chief Marketing Officer at NetApp. “Digital data is collected by the cars’ many sensors as they dart along the track and is processed synchronously to predict outcomes to aid the trackside team. Data equals speed.”

Additional Resources

About NetApp

NetApp is a global, cloud-led, data-centric software company that empowers organizations to lead with data in the age of accelerated digital transformation. The company provides systems, software and cloud services that enable them to run their applications optimally from data center to cloud, whether they are developing in the cloud, moving to the cloud, or creating their own cloudlike experiences on premises. With solutions that perform across diverse environments, NetApp helps organizations build their own data fabric and securely deliver the right data, services and applications to the right people—anytime, anywhere. Learn more at www.netapp.com or follow us on Twitter, LinkedIn, Facebook, and Instagram.

NETAPP, the NETAPP logo, and the marks listed at www.netapp.com/TM are trademarks of NetApp, Inc.

About Porsche in Formula E

With the Porsche 99X Electric, Porsche returned to open-wheel single-seater racing in 2019 after more than 30 years and celebrated a successful debut scoring second place at the season-opener in Saudi Arabia’s Diriyah in the ABB Formula E season 6. In 2021/2022, the TAG Heuer Porsche Formula E Team contests its third Formula E season with the Porsche 99X Electric – and clinched an historic one-two result in Mexico on 12 February 2022. The fully electric racing car sporting the Weissach-developed Porsche E Performance Powertrain also serves as a development platform for the sports car manufacturer’s fully electric production models. Energy management and efficiency are important factors of success in Formula E and in the development of production cars. For the 2021/2022 season, the 99X Electric has a maximum output of 250 kW in qualification mode and 220 kW (last season 200 kW) in normal race mode. Attack Mode boosts the output to 250 kW (last season 235 kW). Maximum recuperation is 250 kW; the usable battery capacity is 52 Kilowatt-hours.

Formula E is the Fédération Internationale de l'Automobile’s (FIA) innovative and sustainable international championship for electric open-wheel racing cars.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media Contacts:
Kenya Hayes
NetApp
kenya.hayes@netapp.com

Marvin Sauer
NetApp
marvin.sauer@netapp.com

Viktoria Wohlrapp
Porsche
viktoria.wohlrapp@porsche.de

Investor Contact:
Lance Berger
NetApp
lance.berger@netapp.com

About Business Wire

Business Wire
Business Wire



http://www.businesswire.com

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release

Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This

IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 13:38:00 EEST | Press release

For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye